EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study

Giacomo Montagna iD, Alison Laws iD, Massimo Ferrucci iD, Mary M Mrdutt, Susie X Sun iD, Suleyman Bademler iD, Hakan Balbaloglu, Nora Balint-Lahat, Maggie Banys-Paluchowski, Andrea V Barrio, John Benson, Nuran Bese und 39 weitere

Journal of Clinical Oncology · 2025-03 · 43 (7) · 810-820

DOI: 10.1200/jco.24.01052 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Giacomo Montagna und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymph Nodes, Sentinel Lymph Node. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates of additional positive lymph nodes (LNs) at axillary lymph node dissection (ALND) and oncologic outcomes in patients with ypN0i+ treated with and without ALND. METHODS The Oncoplastic Breast Consortium-05/ICARO cohort study (ClinicalTrials.gov identifier: NCT06464341 ) retrospectively analyzed data from patients with stage I to III breast cancer with ITCs in SLNs after NAC from 62 centers in 18 countries. The primary end point was the 3-year rate of any axillary recurrence. The rate of any invasive recurrence was the secondary end point. RESULTS In total, 583 patients were included, of whom 182 (31%) had completion ALND and 401 (69%) did not. The median age was 48 years. Most patients (74%) were clinically node-positive at diagnosis and 41% had hormone receptor–positive/human epidermal growth factor receptor 2–negative tumors. The mean number of SLNs with ITCs was 1.2. Patients treated with ALND were more likely to present with cN2/3 disease (17% v 7%, P < .001), have ITCs detected on frozen section (62% v 8%, P < .001), have lymphovascular invasion (38% v 24%, P < .001), and receive adjuvant chest wall (89% v 78%, P = .024) and nodal radiation (82% v 75%, P = .038). Additional positive nodes were found at ALND in 30% of patients, but only 5% had macrometastases. The 3-year rates of any axillary and any invasive recurrence were 2% (95% CI, 0.95 to 3.6) and 11% (95% CI, 8 to 14), respectively, with no statistical difference by type of axillary surgery. CONCLUSION The nodal burden in patients with ypN0(i+) was low, and axillary recurrence after ALND omission was rare in patients selected for this approach. These results do not support routine ALND in all patients with ypN0(i+).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymph NodesSentinel Lymph NodeAdultAgedFemaleHumansMiddle AgedAxillaChemotherapy, AdjuvantLymph Node ExcisionLymphatic MetastasisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualRetrospective StudiesSentinel Lymph Node BiopsyTreatment Outcome

Autor:innen und Institutionen

  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA.
  • Veneto Institute of Oncology, Padua, Italy.
  • Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN.
  • Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Institute of Oncology, Istanbul University, Istanbul, Turkey.

ORCID-Profile: Giacomo Montagna, Alison Laws, Massimo Ferrucci, Susie X Sun, Suleyman Bademler, Judy C Boughey, Marissa K Boyle, Ruth Eller, Martin Heidinger, Güldeniz Karadeniz Cakmak, Susan B Kesmodel, Tari A King, Francesco Milardi, Dawid Murawa, Tehillah S Menes, Daniele Passeri, Jessica M Pastoriza, Andraz Perhavec, Natália Polidorio, Avina Rami, M Umit Ugurlu, Annemiek van Hemert, Tae-Kyung Robyn Yoo, Jennifer Q Zhang, Marie-Jeanne Vrancken Peeters, Monica Morrow, Walter P Weber

Förderung

  • NCI NIH HHS

Zitieren

APA

Montagna, G., Laws, A., Ferrucci, M., Mrdutt, M. M., Sun, S. X., Bademler, S., Balbaloglu, H., Balint-Lahat, N., Banys-Paluchowski, M., Barrio, A. V., Benson, J., Bese, N., Boughey, J. C., Boyle, M. K., Diego, E. J., Eden, C., Eller, R., Goldschmidt, M., Hlavin, C., …, & ICARO Study Group (2025). Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. Journal of Clinical Oncology, 43(7), 810-820. https://doi.org/10.1200/jco.24.01052

Vancouver

Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, et al. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. Journal of Clinical Oncology. 2025;43(7):810-820. doi:10.1200/jco.24.01052

BibTeX
@article{Montagna2025,
  author = {Montagna, Giacomo and Laws, Alison and Ferrucci, Massimo and Mrdutt, Mary M and Sun, Susie X and Bademler, Suleyman and Balbaloglu, Hakan and Balint-Lahat, Nora and Banys-Paluchowski, Maggie and Barrio, Andrea V and Benson, John and Bese, Nuran and Boughey, Judy C and Boyle, Marissa K and Diego, Emilia J and Eden, Claire and Eller, Ruth and Goldschmidt, Maite and Hlavin, Callie and Heidinger, Martin and Jelinska, Justyna and Karadeniz Cakmak, Güldeniz and Kesmodel, Susan B and King, Tari A and Kuerer, Henry M and Loesch, Julie and Milardi, Francesco and Murawa, Dawid and Moo, Tracy-Ann and Menes, Tehillah S and Passeri, Daniele and Pastoriza, Jessica M and Perhavec, Andraz and Pislar, Nina and Polidorio, Natália and Rami, Avina and Ryu, Jai Min and Schulz, Alexandra and Sevilimedu, Varadan and Ugurlu, M Umit and Uras, Cihan and van Hemert, Annemiek and Wong, Stephanie M and Yoo, Tae-Kyung Robyn and Zhang, Jennifer Q and Karanlik, Hasan and Cabioğlu, Neslihan and Peeters, Marie-Jeanne Vrancken and Morrow, Monica and Weber, Walter P and ICARO Study Group, ICARO Study Group},
  title = {Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {7},
  pages = {810--820},
  doi = {10.1200/jco.24.01052}
}
Kostenlos starten →